Circulating Tumor BRAF Mutation and Personalized Thyroid Cancer Treatment.
作者信息
Khatami Fatemeh, Larijani Bagher, Tavangar Seyed Mohammad
机构信息
Chronic Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute,Tehran University of Medical Sciences, Tehran, Iran. Email:
出版信息
Asian Pac J Cancer Prev. 2017 Feb 1;18(2):293-294. doi: 10.22034/APJCP.2017.18.2.293.
Abstract
摘要
相似文献
1
Circulating Tumor BRAF Mutation and Personalized Thyroid Cancer Treatment.循环肿瘤BRAF突变与甲状腺癌个体化治疗
Asian Pac J Cancer Prev. 2017 Feb 1;18(2):293-294. doi: 10.22034/APJCP.2017.18.2.293.
2
The prevalence and prognostic value of BRAF mutation in thyroid cancer.BRAF突变在甲状腺癌中的患病率及预后价值
Ann Surg. 2007 Sep;246(3):466-70; discussion 470-1. doi: 10.1097/SLA.0b013e318148563d.
3
BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications.甲状腺乳头状癌中的BRAF突变：致病作用、分子基础及临床意义。
Endocr Rev. 2007 Dec;28(7):742-62. doi: 10.1210/er.2007-0007. Epub 2007 Oct 16.
4
[BRAF mutation and papillary thyroid cancer].[BRAF突变与甲状腺乳头状癌]
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2012 Apr;37(4):370-3. doi: 10.3969/j.issn.1672-7347.2012.04.009.
5
Circulating cell-free DNA, SLC5A8 and SLC26A4 hypermethylation, BRAF(V600E): A non-invasive tool panel for early detection of thyroid cancer.循环游离 DNA、SLC5A8 和 SLC26A4 高甲基化、BRAF(V600E)：甲状腺癌早期检测的非侵入性工具面板。
Biomed Pharmacother. 2013 Oct;67(8):723-30. doi: 10.1016/j.biopha.2013.06.007. Epub 2013 Jul 5.
6
c-Met-mediated reactivation of PI3K/AKT signaling contributes to insensitivity of BRAF(V600E) mutant thyroid cancer to BRAF inhibition.c-Met介导的PI3K/AKT信号通路重新激活导致BRAF（V600E）突变型甲状腺癌对BRAF抑制不敏感。
Mol Carcinog. 2016 Nov;55(11):1678-1687. doi: 10.1002/mc.22418. Epub 2015 Oct 12.
7
Correlation of BRAFV600E Mutation and Glucose Metabolism in Thyroid Cancer Patients: An ¹⁸F-FDG PET Study.甲状腺癌患者BRAFV600E突变与糖代谢的相关性：一项¹⁸F-FDG PET研究
J Nucl Med. 2015 May;56(5):662-7. doi: 10.2967/jnumed.114.150607. Epub 2015 Mar 26.
8
Clinicopathologic implications of the BRAF(V600E) mutation in papillary thyroid cancer: a subgroup analysis of 3130 cases in a single center.甲状腺癌 BRAF(V600E) 突变的临床病理意义：单中心 3130 例病例的亚组分析。
Thyroid. 2013 Nov;23(11):1423-30. doi: 10.1089/thy.2013.0036. Epub 2013 Sep 27.
9
Selective growth inhibition in BRAF mutant thyroid cancer by the mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244.丝裂原活化蛋白激酶激酶1/2抑制剂AZD6244对BRAF突变型甲状腺癌的选择性生长抑制作用
J Clin Endocrinol Metab. 2007 Dec;92(12):4712-8. doi: 10.1210/jc.2007-1184. Epub 2007 Sep 18.
10
Detectable BRAF mutation in serum DNA samples from patients with papillary thyroid carcinomas.检测甲状腺乳头癌患者血清 DNA 样本中的 BRAF 突变。
Head Neck. 2010 Feb;32(2):229-34. doi: 10.1002/hed.21178.
引用本文的文献
1
Liquid Biopsy as a Minimally Invasive Source of Thyroid Cancer Genetic and Epigenetic Alterations.液体活检作为甲状腺癌遗传和表观遗传改变的微创来源
Int J Mol Cell Med. 2019 Winter;8(Suppl1):19-29. doi: 10.22088/IJMCM.BUMS.8.2.19. Epub 2019 May 29.
2
Liquid Biopsy: The Unique Test for Chasing the Genetics of Solid Tumors.液体活检：追踪实体瘤遗传学的独特检测方法。
Epigenet Insights. 2020 Feb 28;13:2516865720904052. doi: 10.1177/2516865720904052. eCollection 2020.
3
The Impact Of Gene (SDH) Mutations In Renal Cell Carcinoma (RCC): A Systematic Review.基因（SDH）突变在肾细胞癌（RCC）中的影响：一项系统综述。
Onco Targets Ther. 2019 Sep 26;12:7929-7940. doi: 10.2147/OTT.S207460. eCollection 2019.
4
Personalized treatment options for thyroid cancer: current perspectives.甲状腺癌的个性化治疗方案：当前观点
Pharmgenomics Pers Med. 2019 Sep 13;12:235-245. doi: 10.2147/PGPM.S181520. eCollection 2019.
5
Oncometabolites as biomarkers in thyroid cancer: a systematic review.癌代谢物作为甲状腺癌生物标志物的系统评价
Cancer Manag Res. 2019 Feb 25;11:1829-1841. doi: 10.2147/CMAR.S188661. eCollection 2019.
6
A Review of Driver Genetic Alterations in Thyroid Cancers.甲状腺癌驱动基因改变综述
Iran J Pathol. 2018 Spring;13(2):125-135. Epub 2018 Jul 17.
7
Liquid Biopsy in Thyroid Cancer: New Insight.甲状腺癌中的液体活检：新见解
Int J Hematol Oncol Stem Cell Res. 2018 Jul 1;12(3):235-248.
8
Circulating tumor DNA (ctDNA) in the era of personalized cancer therapy.个性化癌症治疗时代的循环肿瘤DNA（ctDNA）
J Diabetes Metab Disord. 2018 Mar 26;17(1):19-30. doi: 10.1007/s40200-018-0334-x. eCollection 2018 Jun.
9
Multiple Endocrine Neoplasia Syndromes from Genetic and Epigenetic Perspectives.从遗传和表观遗传学角度看多发性内分泌肿瘤综合征
Biomark Insights. 2018 Jul 2;13:1177271918785129. doi: 10.1177/1177271918785129. eCollection 2018.
10
Current Diagnostic Status of Pheochromocytomaand Future Perspective: A Mini Review.嗜铬细胞瘤的当前诊断现状与未来展望：一篇综述短文
Iran J Pathol. 2017 Summer;12(3):313-322. Epub 2017 Jul 1.
本文引用的文献
1
The Potential of Circulating Tumor Cells in Personalized Management of Breast Cancer: A Systematic Review.循环肿瘤细胞在乳腺癌个体化管理中的潜力：一项系统综述。
Acta Med Iran. 2017 Mar;55(3):175-193.
2
Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial.维莫非尼用于放射性碘难治性BRAF（V600E）阳性转移性或不可切除性乳头状甲状腺癌患者：一项非随机、多中心、开放标签的2期试验。
Lancet Oncol. 2016 Sep;17(9):1272-82. doi: 10.1016/S1470-2045(16)30166-8. Epub 2016 Jul 23.
3
Changing Trends in the Incidence of Thyroid Cancer in the United States.美国甲状腺癌发病率的变化趋势
JAMA Otolaryngol Head Neck Surg. 2016 Jul 1;142(7):709-11. doi: 10.1001/jamaoto.2016.0230.
4
Cell-free circulating tumor DNA in cancer.癌症中的游离循环肿瘤DNA
Chin J Cancer. 2016 Apr 7;35:36. doi: 10.1186/s40880-016-0092-4.
5
Genomically Driven Tumors and Actionability across Histologies: BRAF-Mutant Cancers as a Paradigm.基因组驱动的肿瘤及不同组织学类型的可靶向性：以BRAF突变型癌症为例
Mol Cancer Ther. 2016 Apr;15(4):533-47. doi: 10.1158/1535-7163.MCT-15-0643. Epub 2016 Mar 23.
6
Evolving molecularly targeted therapies for advanced-stage thyroid cancers.晚期甲状腺癌的分子靶向治疗进展。
Nat Rev Clin Oncol. 2016 Jul;13(7):403-16. doi: 10.1038/nrclinonc.2016.19. Epub 2016 Mar 1.
7
Application of Sequencing, Liquid Biopsies, and Patient-Derived Xenografts for Personalized Medicine in Melanoma.测序、液体活检和患者来源异种移植在黑色素瘤个性化医疗中的应用
Cancer Discov. 2016 Mar;6(3):286-99. doi: 10.1158/2159-8290.CD-15-1336. Epub 2015 Dec 29.
8
Real-time liquid biopsies become a reality in cancer treatment.实时液体活检在癌症治疗中成为现实。
Ann Transl Med. 2015 Mar;3(3):36. doi: 10.3978/j.issn.2305-5839.2015.01.16.
9
"Molecular profiling and ways towards personalized medicine in advanced differentiated thyroid cancer".晚期分化型甲状腺癌的分子剖析与个性化医疗之路
Curr Genomics. 2014 Jun;15(3):161. doi: 10.2174/138920291503140609094751.
10
Real-time liquid biopsy in cancer patients: fact or fiction?癌症患者的实时液体活检：现实还是虚构？
Cancer Res. 2013 Nov 1;73(21):6384-8. doi: 10.1158/0008-5472.CAN-13-2030. Epub 2013 Oct 21.
Zotero 插件